Zepp Health Corporation (ZEPP) 株式分析

企業概要

Zepp Health Corporation is a global technology enterprise dedicated to the development of smart wearable devices and health monitoring solutions that optimize user fitness and wellness journeys. The company operates within the Technology sector, specifically serving the Consumer Electronics industry, which implies a focus on hardware manufacturing and software integration for end-user devices. Zepp Health Corporation currently maintains a market capitalization of $168.48M and reports an annual revenue of $258.90M, while the specific employee count is not disclosed in available public records. These financial metrics indicate that the company operates with a small-cap valuation profile, suggesting it is a growth-oriented entity that has yet to achieve profitability, as evidenced by its significant revenue generation against a negative net income position.

財務健全性

The company reported revenue of $258.90M over the trailing twelve months, yet this top-line performance resulted in a net income loss of $40.068M and an EBITDA of -$24.213M, revealing a cost structure where operating expenses and losses significantly outweigh gross profits. Although the free cash flow metric is not currently available, the presence of $57.05M in cash reserves alongside $116.31M in total debt suggests a balance sheet that is heavily leveraged rather than conservative. The debt-to-equity ratio stands at 54.21, which indicates a high reliance on financial leverage to fund operations and growth initiatives. Gross margin is reported at 38.3%, demonstrating the company retains a substantial portion of revenue after cost of goods sold, yet this is eroded by operating expenses to result in an operating margin of -4.5% and a profit margin of -15.5%. The current ratio of 1.02 indicates that the company's current assets barely exceed its current liabilities, pointing to tight short-term liquidity conditions that require careful management of working capital. Furthermore, the return on equity is -17.2% and the return on assets is -3.3%, metrics that collectively reveal that management has not yet generated positive returns on the capital invested in the business.

バリュエーション評価

The trailing twelve months P/E ratio is not available due to negative earnings, while the forward P/E is listed as -1152.00, a figure that implies earnings are currently negative and any future valuation multiple would depend on a return to profitability. The price-to-book ratio is 0.85, indicating that the market values the company's equity at a discount relative to its book value, which often occurs with unprofitable technology firms. Alternative valuation metrics such as the price-to-sales ratio of 0.65 and the EV/EBITDA of -123.31 suggest that the stock is priced based on revenue generation rather than earnings power or cash flow generation. The stock has traded between a 52-week low of $2.12 and a 52-week high of $61.85, meaning the current price sits significantly below the recent highs but remains well above the yearly lows. With a beta of 1.77, the company's stock price exhibits high volatility that is 77% greater than the broader market, reflecting the inherent risks associated with small-cap technology stocks in the consumer electronics space.

Growth & Income

Zepp Health Corporation achieved a revenue growth rate of 43.0% year-over-year, whereas earnings growth is not applicable due to the company's ongoing losses, indicating that top-line expansion is occurring without corresponding bottom-line profitability. Since the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm retains all earnings to fund operations and future growth rather than returning capital to shareholders. This reinvestment strategy is typical for pre-profitability technology companies seeking to scale their consumer brands, such as Amazfit and Zepp Clarity, to capture market share in the global wearable health market. The overall growth and income profile is characterized by robust revenue expansion coupled with significant operating losses and no current income distribution, highlighting a pure growth phase where capital efficiency has not yet been realized.